January 18th, 2021
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
Registration-enabling study expected to begin dosing in the second or third quarter of this year Inhibrx, Inc….
Read Article